Research and development company, APC, has announced the completion of a €10 million investment expanding its facilities at its headquarters in Cherrywood, Dublin. APC partners with the pharmaceutical and biotech industry to accelerate the development of life-changing medicines to patients. Currently APC is working on more than 20 medicines for a variety of cancers, respiratory diseases, Alzheimer’s and HIV.
Fifty new research and development positions will be created at the new biotech facility.
APC currently employs 120 people, the majority of which are chemical engineers, process and biopharmaceutical scientists. The company is the largest employer in Ireland of PhD qualified chemical engineers and one of the country’s largest employers of PhD-level scientists. The new facility announced today will grow the Cherrywood HQ to 60,000 sq.ft, with staff numbers expected to increase by over 40% by the end of 2019.
Mark Barrett, CEO of APC, said the investment represents APC’s continued expansion into new and emerging therapies and technologies such as viral, gene and cell therapies. “We are also delighted that the new facility with Bavarian Nordic will enforce our stated mission of accelerating the development of quality, life-changing medicines to patients.”